SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma
ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle
bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.
Phase:
Early Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio